MannKind Corporation
Inhalable dry powder pharmaceutical composition
Last updated:
Abstract:
A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
Status:
Grant
Type:
Utility
Filling date:
19 Dec 2019
Issue date:
19 Apr 2022